Ruxolitinib

(3R )-3 -cyclopentyl -3- [4 - (7H -pyrrolo [2,3-d ] pyrimidine -4 -yl)- pyrazol- 1-yl] propanenitrile (IUPAC)

L01XE18

Cytostatic

Tyrosine kinase inhibitor

Risk

Template: Infobox chemical / molecular formula search available

Ruxolitinib is a tyrosine kinase inhibitor which is used in certain myeloproliferative neoplasms such as idiopathic ( or primary) myelofibrosis. The drug was approved in 2012 ( trade name Jakafi ®, Jakavi ®) and inhibits the Janus kinases 1 and 2 dose -dependent side effects are anemia and thrombocytopenia.

Indication

The application of Ruxolitinib is indicated for the treatment of primary myelofibrosis and post- polycythemia vera myelofibrosis.

Contraindication

When it falls below the platelet count to < 50.000/μl or the leukocyte count < 500/μl, treatment should be interrupted. In addition, pregnancy and lactation is a contraindication

Dose adjustment

In severe renal impairment with a creatinine clearance of < 30ml/min the dose should be halved

Side effects

The most common side effects are dizziness and headache. A decrease in blood platelets, low white blood cells and bleeding have been reported as side effects in the Phase III studies. Infections and an increase in blood pressure during treatment were more frequent than in placebo-treated patients.

Swell

  • ATC -L01
  • Substance with suspected reproductive toxicity
  • Tyrosine kinase inhibitor
CAS registry number PubChem Anatomical Therapeutic Chemical Classification System DrugBank Tyrosine-kinase inhibitor Januskinase
698457
de